Tag:

Biotech IPO

Latest Headlines

Latest Headlines

Erytech pushes ahead with plan to file IPO on Nasdaq to fund cancer pipeline

Erytech is poised to become the latest in a long line of European biotechs to head to Wall Street in search of cash. The proposal marks an escalation of the cancer biotech's long-running flirtation with U.S. investors, which has already seen it set up on the OTC market and tap stateside sources for its previous fundraising round.

UPDATED: Torrid pace of VC investing in H1 sets a new biotech record

The venture money machine backing the biotech industry in the U.S. was operating in overdrive during the second quarter, generating a record amount of investing in new drug development as IPOs continue their romp in the third year of a wide-open market.

Celgene backing Soon-Shiong's cancer biotech IPO, now dubbed NantKwest

Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created.

Aimmune joins the biotech IPO scrum in search of $115M

Working off of an $80 million crossover round with newly won boasting rights to the FDA's breakthrough therapy designation in hand, Brisbane, CA-based Aimmune Therapeutics is wasting no time in diving into the heated IPO waters for biotech. The biotech filed plans to raise $115 million on Nasdaq, the latest in a scrum of developers anxious to tap into the long-running boom market.

Biotech fledglings crowd into a still-sizzling market for IPOs

Boulder, CO-based Nivalis Therapeutics rode the hot market for biotech IPOs to a $77 million windfall, banking on a very early-stage cystic fibrosis effort that's looking to ride on the coattails of a new combo therapy from Vertex.

Pioneering microbiome upstart Seres Therapeutics targets a $100M IPO

Microbiome pioneer Seres Therapeutics is taking its promising lead therapy and the high expectations for an emerging field in biotech and heading to Wall Street, where it hopes to raise $100 million in an IPO that is likely to provide another litmus test of investors' appetite for new drug technologies.

Kite CEO Arie Belldegrun fills a prescription for tax bite

Death and taxes may both be unavoidable, but Kite Pharma CEO Arie Belldegrun at least knows how to limit the pain on part of that equation.

High-flying immuno-oncology player Adaptimmune pitches $150M IPO

Adaptimmune Therapeutics has become one of the brightest hopes in the U.K. biotech scene, scoring a $350 million collaboration pact with GlaxoSmithKline and a whopping $104 million venture round. Now Adaptimmune--a 2014 Fierce 15 company--will see if it can keep the hot streak rolling with a $150 million IPO pitch.

Flagship banks $537M to back the next batch of biotechs

Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.

Summit pulls off a downsized IPO for its DMD drug

The U.K.'s Summit Therapeutics is elbowing its way into the race to treat Duchenne muscular dystrophy, pulling off a $34 million U.S. IPO to fund its research.